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Abstract: Gulf War Illness (GWI) is a persistent chronic neuroinflammatory illness exacerbated by
external stressors and characterized by fatigue, musculoskeletal pain, cognitive, and neurological
problems linked to underlying immunological dysfunction for which there is no known treatment.
As the immune system and the brain communicate through several signaling pathways, including the
hypothalamic–pituitary–adrenal (HPA) axis, it underlies many of the behavioral and physiological
responses to stressors via blood-borne mediators, such as cytokines, chemokines, and hormones.
Signaling by these molecules is mediated by the semipermeable blood–brain barrier (BBB) made up
of a monocellular layer forming an integral part of the neuroimmune axis. BBB permeability can be
altered and even diminished by both external factors (e.g., chemical agents) and internal conditions
(e.g., acute or chronic stress, or cross-signaling from the hypothalamic–pituitary–gonadal (HPG)
axis). Such a complex network of regulatory interactions that possess feed-forward and feedback
connections can have multiple response dynamics that may include several stable homeostatic states
beyond normal health. Here we compare immune and hormone measures in the blood of human
clinical samples and mouse models of Gulf War Illness (GWI) subtyped by exposure to traumatic
stress for subtyping this complex illness. We do this via constructing a detailed logic model of
HPA–HPG–Immune regulatory behavior that also considers signaling pathways across the BBB to
neuronal–glial interactions within the brain. We apply conditional interactions to model the effects
of changes in BBB permeability. Several stable states are identified in the system beyond typical
health. Following alignment of the human and mouse blood profiles in the context of the model,
mouse brain sample measures were used to infer the neuroinflammatory state in human GWI and
perform treatment simulations using a genetic algorithm to optimize the Monte Carlo simulations of
the putative treatment strategies aimed at returning the ill system back to health. We identify several
ideal multi-intervention strategies and potential drug candidates that may be used to treat chronic
neuroinflammation in GWI.
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1. Introduction
Gulf War Illness (GWI) is a chronic disorder that affects up to one-third of the
700,000 veterans of the Persian Gulf War of 1991. Many symptoms of GWI, including
fatigue, musculoskeletal pain, cognitive, and neurological problems [1], are indicative of
a neuroinflammatory disorder, and abnormal regulation of the hypothalamic–pituitary–
adrenal (HPA) axis, a key component in the body’s stress response, has been associated
with this chronic condition [2–6]. Yet, the cause and underlying mechanisms of GWI are
still relatively unknown, and there is no known treatment. Progress needs to be made to
provide relief to this aging population, but the heterogeneity of the illness presentation
provides complications. Subtyping the illness is one option to improve diagnostics and
identify potential subtype-specific treatment avenues.
Possible explanations for the cause of GWI include exposure to mild traumatic brain
injury and chemical/biological weapons [7] as well as the involvement of a neuroinflam-
matory signaling cascade triggered by exposure to a neurotoxin (e.g., the organophosphate
sarin) and exposure to a combat environment [8–10]. Genetic susceptibility [11,12] of
veterans may further contribute to the resulting changes in brain function observed in
GWI [13–15]. Furthermore, confounding and/or exacerbating factors often complicate
this diagnosis. Veterans suffering from GWI are often also diagnosed with post-traumatic
stress disorder (PTSD) [16,17]. A population-based study estimates that 35% of veterans
with GWI also suffer from PTSD [18], which exacerbates all the overall clinical symptoms
of GWI [19]. As there is a substantial overlap of PTSD symptoms with the symptoms
defining GWI [20], with both PTSD [21–24] and GWI [6,25,26] exhibiting immunological
dysfunction and abnormal neural synchrony [14], this suggests that GWI and PTSD share
several core pathophysiological processes and that these processes may be altered in the
context of co-morbidity. As such, the presence or absence of PTSD in GWI provides one
mean to subtype this illness.
While the immune system, as an independent agent, provides the human body with a
defense system that protects against foreign proteins and chemicals, it cannot be considered
independent from the body as a whole, or the brain in particular. The brain plays a critical
role in the regulation and modulation of immunity, effectively integrating the nervous
and immune systems, the two most complex systems of the body for the maintenance of
homeostasis, into one. The study of these neuroimmune interactions along with the en-
docrine system and resulting behaviors is collectively known as psychoneuroimmunology
and studying the functional significance of the relationships among these systems is the
focus of the field. Analyzing the mechanisms that functionally alter this single overarching
system can lead to a significantly enhanced understanding of the unique and combined
contributions of hormones, the brain, behavior, and the immune system to health and
disease.
The immune system and the brain communicate through several signaling pathways.
Two of the major pathways involved in this crosstalk are the sympathetic nervous sys-
tem via the sympathetic–adrenal–medullary axis and the hypothalamic–pituitary–adrenal
(HPA) axis. Both release blood-borne mediators, including cytokines, chemokines, and
hormones, which are then subject to further regulation. The brain and spinal cord, which
comprise the central nervous system (CNS), are kept isolated from signaling in the blood
flow of the peripheral body by a monocellular interface called the blood–brain barrier
(BBB). This division is made possible by several parallel barriers that include most notably
the capillary bed of the CNS and the choroid plexus. These barriers at one level create the
dichotomy between the circulating factors of the immune system and the components of
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the CNS only to regulate the interactions between the immune system and the CNS at other
levels. The BBB is thus an integral part of the neuroimmune axis. Many factors, includ-
ing stress, regulate the permeability of the BBB. Corticotropin-releasing hormone (CRH),
released by the HPA axis during times of stress, has proinflammatory effects mediated
through mast cells, which regulate BBB permeability [27,28]. Furthermore, CRH release
leads to the secretion of catecholamines and glucocorticoids, which exert their effects on
the BBB. Exposure to acute or chronic stress activates the HPA axis, whether the stressor is
mental or physiological distress, even inducing, and can lead to BBB breakdown [27,28].
Not only is the HPA axis activated by stress, HPA activity is also tied to both the
hypothalamic–pituitary–gonadal (HPG) axis and the immune system, among others, and is
further influenced by brain signaling outside the hypothalamus. Moreover, weakening the
BBB can lead to additional or enhanced interactions among these and other systems. This
level of integrated connectivity is core to the body’s adaptive capability and contributes to
its resilience and vulnerabilities. As the HPA axis plays a crucial role in the body’s response
to stress [29–31] and is one of the major information pathways connecting the peripheral
systems to the CNS, several mathematical models of HPA dynamics have been proposed
to understand its function [32–37]. Few models account for its detailed feed-forward
regulation [37], but this is highly relevant as signaling networks such as the HPA axis do
not work in isolation. Even fewer account for its connection to other bodily systems.
A complex network of regulatory interactions that possess feed-forward and feedback
connections, such as the aforementioned neuro-immune axis, can have multiple response
dynamics that may include several stable homeostatic states beyond a normal healthy
state [38–46]. Due to homeostatic feedback mechanisms, acute or minor changes to this
system return to the baseline, or a normal healthy state. Nevertheless, under more severe
perturbations, the system may shift from a normal homeostatic state to a new stable state.
This disturbance may consist of a single event or an ongoing external insult that further
changes the underlying dynamics. We believe that these regulatory alterations are a key
cause of the resistance to therapy seen in neuroinflammatory illnesses and may explain
some of the hardships in attaining lasting remission. By identifying and detailing these
alternative homeostatic regimes, it may be possible to design treatments aimed at returning
the overall system back to its original healthy state.
In this work, we propose to build on our ongoing research directed at mapping com-
plex inflammatory mechanisms in GWI to improve our understanding of the immunologic
underpinnings of GWI, the compounding effects of co-morbidity with PTSD, and the
potential of this comorbidity to define a unique subtype of GWI. Furthermore, we propose
to take advantage of our ongoing work in predictive modeling to assess possible changes
to putative treatments of GWI in the context of a probable PTSD diagnosis or lack thereof.
We do this by constructing a logic model representation of the neuroimmune system across
the BBB connecting the CNS to the peripheral immune system. As we cannot assess the
neuroimmune state in the brain of living GWI subjects, we topologically compare the
model results of a GWI cohort with and without PTSD symptoms to mouse models of
GWI in blood and use the corresponding neuroimmune states in mouse brain to infer
the blood–brain state of the GWI subjects. This inference is then used to guide predictive
modeling of treatment courses designed to return the overall neuroimmune system to
healthy regulation.
2. Results
2.1. The GWI Cohort
The total cohort used in this study was comprised of 89 male veterans recruited
through the Miami Veterans Affairs (VA) Medical Health Center. The average age of the
cohort was 43.68 ± 7.42 years with an average BMI of 29.49 ± 5.42. The sample consisted
of 2.2% Asian, 22.5% Black, 46.1% White Hispanic, 28.1% White, and 1.1% Other. The full
demographics are presented in Table 1.
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Table 1. GWI cohort demographics.
Group Total GWI GWIH GWIL HC p3 p2
n 89 51 32 19 38
Mean Age (y) 43.7 ± 7.4 43.8 ± 5.7 44.4 ± 5.0 42.8 ± 6.7 43.5 ± 9.3 0.991 0.979
Mean BMI 29.5 ± 5.4 30.3 ± 4.6 30.3 ± 4.1 30.2 ± 5.4 28.5 ± 5.4 0.958 0.803
Race 0.318 0.245
Asian 2.2% 3.9% 3.1% 5.3% 0.0%
Black 22.5% 27.5% 34.4% 15.8% 15.8%
Hispanic 46.1% 39.2% 40.6% 36.8% 55.3%
White 28.1% 29.4% 21.9% 42.1% 26.3%
Other 1.1% 0.0% 0.0% 0.0% 2.6%
Marital Status 0.755 0.838
Married 62.9% 64.7% 71.9% 52.6% 60.5%
Widowed 1.1% 0.0% 0.0% 0.0% 2.6%
Divorced 12.4% 13.7% 12.5% 15.8% 10.5%
Separated 3.4% 3.9% 3.1% 5.3% 2.6%
Never Married 9.0% 7.8% 9.4% 5.3% 10.5%
Not Answered 11.2% 9.8% 3.1% 21.1% 13.2%
Employed 75.3% 70.6% 68.8% 73.7% 81.6% 0.456 0.234
Mean
Schooling (y) 15.5 ± 2.5 15.3 ± 2.6 15.7 ± 2.8 15.4 ± 2.0 15.8 ± 2.8 0.994 0.907
The full sample included n = 51 male veterans meeting the criteria for GWI in addition
to n = 38 healthy sedentary veteran controls (HC). McDonald et al. (2014) [47] examined
the diagnostic accuracy of applying a cut score method to the Davidson Trauma Score
(DTS) in a population of U.S. military veterans and found that using a cut score of 70 for the
total DTS score offered optimal diagnostic accuracy, correctly classifying 90% of cases and
providing an accurate estimate of PTSD population prevalence. Of the 51 GWI subjects,
n = 32 had a total DTS of 70 or greater. The group of GWI subjects with DTS scores above
70 are considered to have a high probability of having PTSD and are denoted as GWIH,
while the remainder have a low probability of having PTSD and labelled as GWIL.
Statistical comparisons (Table 1) were made between both the total GWI and HC
groups (p2) as well as between the GWIH, GWIL, and HC groups (p3), using ANOVA for
the continuous variables and the χ2 test for categorical variables. No statistical differences
were found in age, BMI, racial representation, marital status, employment status, or average
number of years in school.
Blood plasma cytokine levels for the GWI subgroups at rest (T0) and peak effort in
a maximal graded exercise test (T1) as compared to HC at rest are presented in Figure 1.
Statistical comparisons were made using heteroscedastic two-tailed t-tests between the
GWI subgroups and HC at both timepoints, and between the GWI subgroups within
each timepoint. While there appears to be trends of immune dysregulation in the GWI
subgroups at rest, there were no statistical differences between the GWI subgroups and
HC or between the two subgroup conditions, owing to the large degree of variability
within the measures. After immune stimulation via the graded exercise challenge the
immune profiles of the GWI subgroups again show trends of immune dysregulation with
several statistically significant differences, namely, elevated IL-8, IFN-γ, and TNFα in both
subgroups, depressed IL-4 in GWIL, and elevated IL-1β in GWIH. Again, owing to the
large degree of variability in the measures, no significant differences were found between
the GWI subgroups at T1.




Figure 1. Human blood cytokine levels in PTSD-based GWI subtypes as compared to HC at rest (T0) 
and peak exercise during a maximal graded exercise challenge (T1). Individual cytokine values are 
normalized to the HC values, and bars represent the mean ratios ± SEM for each cytokine. Signifi-
cance was set at * p < 0.05, ** p < 0.01, and *** p < 0.001 as compared to HC. The false discovery rate, 
as calculated via Storey et al. [48], was < 0.1 for all significant measures. Values are found in Table 
S1. 
2.2. A Long-Term Mouse Model of Gulf War Illness 
Veterans with GWI had the potential to be exposed to several toxicants during their 
deployment, as well as to adverse environmental conditions [49]. Previously, a GWI ani-
mal model was established that attempted to capture the concomitant exposure to neuro-
toxic agents and high physiological stress, such as excessive heat and exercise, that was 
likely experienced during deployment by many of the veterans with GWI. By combining 
exposure to the sarin nerve agent surrogate diisopropyl fluorophosphate (DFP) with prior 
subchronic exposure to the stress hormone corticosterone (CORT), it was shown that these 
exposures produce significantly exacerbated neuroinflammation and pain responses, as 
well as changes in the structure and cellular biology of the brain and glia [50–61]. While 
these results have been found acutely following exposure, they have begun to be sup-
ported in current evaluations of veterans with GWI by various imaging methods, finding 
evidence of both neuroinflammation [13] and brain structural changes indicative of the 
restructuring of the glia [62]. As such, it was important to investigate the impacts of these 
initial CORT and DFP exposures at longer-term time points that are more relevant to the 
current condition of veterans with GWI. Thus, to further represent the protracted nature 
of GWI (i.e., 30 years since the initiating event), mice were aged for a total of 11 weeks 
with either H2O or repeated exposure to 4-day bouts of CORT every other week to reflect 
ongoing stress, with the potential to be representative of PTSD, following the initial expo-
sure to CORT and DFP as utilized in previous studies (Figure 2A) [50–61]. Following this, 
a lipopolysaccharide (LPS) challenge was used to stimulate the immune system in lieu of 
exercise. To gauge the effect of the DFP exposure and LPS challenge, saline solution (SL) 
was used as a control. This resulted in five mouse groups analogous to the human cohort 
(H2O SL SL = HC; H2O DFP SL = GWIL T0; CORT DFP SL = GWIH T0; H2O DFP LPS = 
GWIL T1; and CORT DFP LPS = GWIH T1). 
Serum cytokine levels for the GWI mouse model groups as compared to the H2O SL 
SL control are presented in Figure 2B. Statistical comparisons were made using heterosce-
dastic two-tailed t-tests between all GWI mouse model groups and the H2O SL SL control 
for both rest and LPS immune challenge timepoints, and within challenge groups for the 
H2O and CORT conditions. While the majority of measures for the unchallenged groups 
show no significant differences, there are statistical differences between the unchallenged 
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in current evaluations of veterans with GWI by various imaging methods, finding evidence
of both neuroinflammation [13] and brain structural changes indicative of the restructuring
of the glia [62]. As such, it was important to investigate the impacts of these initial CORT
and DFP exposures at longer-term time points that are more relevant to the current condi-
tion of veterans with GWI. Thus, to further represent the protracted nature of GWI (i.e.,
30 years since the initiating event), mice were aged for a total of 11 weeks with either H2O
or repeated exposure to 4-day bouts of CORT every other week to reflect ongoing stress,
with the potential to be representative of PTSD, following the initial exposure to CORT and
DFP as utilized in previous studies (Figure 2A) [50–61]. Following this, a lipopolysaccha-
ride (LPS) challenge was used to stimulate the immune system in lieu of exercise. To gauge
the effect of the DFP exposure and LPS challenge, saline solution (SL) was used as a control.
This resulted in five mouse groups analogous to the human cohort (H2O SL SL = HC; H2O
DFP SL = GWIL T0; CORT DFP SL = GWIH T0; H2O DFP LPS = GWIL T1; and CORT DFP
LPS = GWIH T1).
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Figure 2. Cytokine expression in a long-term mouse model of Gulf War Illness. (A) Graphical rep-
resentation of the animal dosing paradigm. Mice were exposed to corticosterone (CORT; 200 mg/L 
in 0.6% ethanol) for 4 days at a time every other week for a total of 11 weeks. DFP (4 mg/kg, i.p.) 
was given on Day 5 and the LPS challenge (0.5 mg/kg, s.c.) was given after the final week of CORT. 
(B) Individual serum cytokine values normalized to the water (H2O), saline solution (SL), and SL 
condition values. Bars represent the mean ratios ± SEM for each cytokine. Significance was set at p 
< 0.05 compared to H2O SL SL (*), and within challenge groups (&: H2O DFP SL vs. H2O DFP LPS; 
and #: CORT DFP SL vs. CORT DFP LPS). The false discovery rate, as calculated via Storey et al. 
[48], was <0.1 for all significant measures. (C) Cytokine mRNA was measured in the frontal cortex 
Figure 2. Cytokine expression in a long-term mouse model of Gulf War Illness. (A) Graphical representation of the animal
dosing paradigm. Mice were exposed to corticosterone (CORT; 200 mg/L in 0.6% ethanol) for 4 days at a time every other
week for a total of 11 weeks. DFP (4 mg/kg, i.p.) was given on Day 5 and the LPS challenge (0.5 mg/kg, s.c.) was given
after the final week of CORT. (B) Individual serum cytokine values normalized to the water (H2O), saline solution (SL), and
SL condition values. Bars represent the mea ratios ± SEM for each cytokine. Significance was set at p < 0.05 compared to
H2O SL SL (*), and within challenge groups (&: H2O DFP SL vs. H2O DFP LPS; and #: CORT DFP SL vs. CORT DFP LPS).
The false discovery rate, as calculated via Storey et al. [48], was <0.1 for all significant measures. (C) Cytokine mRNA was
measured in the frontal cortex (n = 2–5/group) by qRT-PCR 6 h following exposure to LPS. Bars represent the mean ± SEM.
Significance was set at p ≤ 0.05 for comparisons within challenge group (*: DFP vs. CORT DFP) or across challenge group
(#: SL vs. LPS). Values for (B,C) are found in Tables S2 and S3, respectively.
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Serum cytokine levels for the GWI mouse model groups as compared to the H2O SL SL
control are presented in Figure 2B. Statistical comparisons were made using heteroscedastic
two-tailed t-tests between all GWI mouse model groups and the H2O SL SL control for
both rest and LPS immune challenge timepoints, and within challenge groups for the H2O
and CORT conditions. While the majority of measures for the unchallenged groups show
no significant differences, there are statistical differences between the unchallenged groups
and the control for IL-1α and IL-1β, and between the unchallenged groups for IL-4 and
IL-5.
The starkest differences are for the CORT DFP LPS group compared to the control and
the non-stressed H2O DFP LPS group for IL-1α, IL-1β, IL-5, IL-6, KC (mouse equivalent of
IL-8), mIL-10, IFNγ, and TNFα. While trends appear for mIL-6 and KC in the H2O DFP
LPS group to be increased over the control, statistical difference is not reached due to large
variance and a small group size.
Brain cytokine mRNA levels for the GWI mouse model groups as compared to the
H2O SL SL control are presented in Figure 2C. Here, again, it is seen that the CORT DFP
LPS group has statistically higher amounts of the proinflammatory cytokines IL-1β, IL-6,
and TNFα than both the control and the other mouse groups. Additionally, this group also
has elevated markers for microglial activation C-C Motif Chemokine Ligand 2 (CCL2) and
oncostatin M (OSM). No other measures showed significant increases from the control or
within groups.
2.3. Male BBB Neuro-Endrocrine-Immune Model
Based on our previous work, we have combined a simple model of the overarching
HPA–HPG–Immune system [38] with a more complex description of the immune func-
tion [39] and a brain compartment describing the neuroimmune interaction of the neurons
and glia [53] (Figure 3).
Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 7 of 27 
(n = 2–5/group) by qRT-PCR 6 h following exposure to LPS. Bars represent the mean ± SEM. Signif-
icance was set at p ≤ 0.05 for comparisons within challenge group (*: DFP vs. CORT DFP) or across 
challenge group (#: SL vs. LPS). Values for (B,C) are found in Tables S2 and S3, respectively. 
The starkest differences are for the CORT DFP LPS group compared to the control and the 
non-stressed H2O DFP LPS group for IL-1α, IL-1β, IL-5, IL-6, KC (mouse equivalent of IL-
8), mIL-10, IFNγ, and TNFα. While trends appear for mIL-6 and KC in the H2O DFP LPS 
group to be increased over the control, statistical difference is not reached due to large 
variance and a small group size. 
Brain cytokine mRNA levels for the GWI mouse model groups as compared to the 
H2O SL SL control are presented in Figure 2C. Here, again, it is seen that the CORT DFP 
LPS group has statistically higher amounts of the proinflammatory cytokines IL-1β, IL-6, 
and TNFα  than both the control and the other mouse groups. Additionally, this group 
also has elevated markers for microglial activation C-C Motif Chemokine Ligand 2 (CCL2) 
and oncostatin M (OSM). No other measures showed significant increases from the con-
trol or within groups.  
2.3. Male BBB Neuro-Endrocrine-Immune Model 
Based on our previous work, we have combined a simple model of the overarching 
HPA–HPG–Immune system [38] with a more complex description of the immune func-
tion [39] and a brain compartment describing the neuroimmune interaction of the neurons 
and glia [53] (Figure 3). 
Figure 3. Theoretical male neuroimmune signaling network. Light blue nodes denote the HPA axis 
model described in [37]. Dark blue nodes denote the male HPG axis as described in [38]. Orange 
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respectively, as originally described in [39]. Grey, yellow, pink, purple, and green nodes on the left 
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ternal influences on the system. Green edges are stimulatory, and red edges are inhibitory. 
Using ternary logic modelling and performing Monte Carlo simulations of state evo-
lution in this theoretical male neuroimmune signaling network identified six potential 
stable behaviors available to the system (Figure 4). The reference stable state (SS0) is that 
of typical health in which all measures are nominally the same as the healthy control 
Figure 3. Theoretical male neuroimmune signaling network. Light blue nodes denote the HPA axis model described in [37].
Dark blue nodes denote the male HPG axis as described in [38]. Orange and green nodes on the right denote a system of
immune signaling molecules and immune cells, respectively, as originally described in [39]. Grey, yellow, pink, purple,
and green nodes on the left denote neuronal–glia interactions, growth factors, blood–brain barrier, neurotransmitter, and
neuroimmune signaling molecules, respectively, as originally described in [53]. Red nodes denote external influences on the
system. Green edges are stimulatory, and red edges are inhibitory.
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Using ternary logic modelling and performing Monte Carlo simulations of state
evolution in this theoretical male neuroimmune signaling network identified six potential
stable behaviors available to the system (Figure 4). The reference stable state (SS0) is that of
typical health in which all measures are nominally the same as the healthy control condition.
The first alternate stable state (SS1) displays a low adrenocorticotropic hormone (ACTH)
concentration with a high glucocorticoid receptor number in both its single membrane
bound (GR) and internalized dimerized (GRD) forms.
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Figure 4. Predicted stable states of the theoretical male neuroimmune signaling network presented in
Figure 3. White fill indicates a nominal state the same as the healthy control (0); green a state higher
than the healthy control (1); and red state lower than healthy control (-1).
The remaining alternate states (SS2, SS3, SS4, and SS5) all present with elevated HPA
axis activity: cortisol, GR, and GRD, and depressed HPG activity: testosterone (TEST),
luteinizing hormone (LH)/follicle-stimulating hormone (FSH), gonadotropin releasing
hormone (GnRH) in addition to depressed natural killer cell activity (NK), and an increase
in monokine (MK) 2 activity (IL-10, IL-22). Beyond this, the second alternate state (SS2)
is distinguished by a periphery marked with elevated chemokines (CK) 2 (interleukin
(IL)-4, IL-5, IL-13), CK17 (IL-17A, IL-17F), MK1 (IL-1α, IL-1β, IL-8, IL-12), MK6 (IL-6),
MK 21 (IL-21), T-helper (Th) 2 cells, Th17B and Th17(23), and depressed MK15 (IL-15),
MK23 (IL-23), MK27 (IL-27), dendritic cells (DC), and T regulatory (Treg) cells. In the
brain compartment, SS2 presents elevated endothelial cell activity, increased T-cell activity,
IL-4, and decreased pro-inflammatory cytokines (IL-1β, IL-6, TNFα), and insulin-like
growth factor 1 (IGF-1). The third alternate state (SS3) presents in the periphery with
elevated CK1 (IL-2, IFNγ, TNFα, TNFβ), cytotoxic lymphocytes (CTL), MK2, and Tregs,
and in the brain with elevated endothelial cell activity, pro-inflammatory cytokines, and
T cell activity, and depressed IL-4 and IGF-1. The fourth alternate state (SS4) likewise
has elevated CK1, CTL, MK2 endothelial cell activity in the periphery, and elevated IL-4
and T-Cells in the brain. Additionally, SS4 displays elevated CK17, MK1, MK6, MK21,
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Th17B, Th17(23), and depressed transforming growth factor β (TGFβ) and Th1 in the
periphery. The final alternate state (SS5) is marked by a periphery with elevated CK1,
CK17, MK1, MK2, MK6, MK15, CTL, Th17B, and Th17(23), and in the brain with elevated
pro-inflammatory cytokines, microglia activity, and vascular endothelial growth factor
(VEGF), and depressed endothelial cell function.
2.4. Alignment of the Blood Profiles with the Model-Predicted States
To determine which of the animal model conditions best represents the GWI cohort
subgroups, to ultimately infer the brain state the GWI cohort subgroups, the above model
describing the known interactions of the neuroimmune system was used to provide a
context for comparisons between human and animal data. To do this, each subgroup
condition in both the human and animal groups was compared to their respective control
condition to determine the degree of agreement with each stable behavior predicted by
the model (Figure 4). Initially, blood profiles for the baseline clinical data obtained from
healthy control patients and data for aged mice receiving a course of pure drinking water,
an initial saline injection, and a follow-up injection of saline were used to define the base
topology of the simulated stable states using Brown’s method, as described in the Materials
and Methods section (Figure 5). As can be seen from Figure 5A,B, the overall topology of
the stable state locations is retained between humans and mice, as evidenced by the relative
spacing between points. However, there is a discrepancy in the actual distance values
between the stable points, owing to the difference in the human and mouse systems. By
comparing the edge-by-edge distances between these networks, a strong linear correlation
between mouse and human data is revealed, which is used to scale the mouse network
data to humans for further analysis (Figure 5C,D).
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Cohort and mouse model subgroup condition blood profiles at rest were then added 
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Figure 5. Reference blood profile topological network. (A) Topology of the distance between the
simulated stable states using Brown’s method based on human healthy control data. (B) Topology
of the distance between the simulated stable states using Brown’s method based on data from mice
receiving a course of pure drinking water, an initial saline injection, and a follow-up injection of
saline. (C) Regression of the human topology onto the mouse topology. (D) Topology of the distance
between the simulated stable states using Brown’s method based on data from mice receiving a
course of pure drinking water, an initial saline injection, and a follow-up injection of saline scaled to
the human topology.
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Cohort and mouse model subgroup condition blood profiles at rest were then added
to the reference blood profile topological networks (Figure 6). The topological profile of the
resulting network for GWIH (Figure 6B) differed from GWIL (Figure 6A) with an RMSD
of 0.42. Similar topological differences are seen for DFP-exposed mice (Figure 6D) with
and without prior treatment with CORT (Figure 6C). The difference between these mice
conditions is comparable to the human conditions given by an RMSD of 0.33.
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rest. (A) Topology of the distance between the simulated stable states for GWIL at rest. (B) Topology
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between the simulated stable states from mice receiving a course of pure drinking water, an injection
of DFP, and a follow-up injection of saline. (D) Topology of the distance between the simulated
stable states from mice receiving a course of drinking water with CORT, an injection of DFP, and a
follow-up injection of saline.
Comparison of the GWI illness conditions to the mouse conditions at rest show
that the GWIL condition is most closely matched by the non-CORT-treated mouse model
(RMSD = 0.06) rather than the CORT-treated model (RMSD = 0.36). The opposite was
shown for the GWIH condition, with the CORT-treated model (RMSD = 0.28) being a better
match over the non-CORT-treated model (RMSD = 0.47). However, despite this agreement
between the trauma/stressed states, there are noticeable differences that account for the
non-zero RMSD. Both GWI illness subtypes show the closest alignment with stable state
SS4/SS5. This difference is driven by GWIH having a large distance from SS0/SS1 and
closer alignment to SS3, while this is reversed for GWIL.
This is not the case for the mouse models as the CORT-treated model shows the closest
alignment with SS3, while the non-CORT-treated model shows the closest alignment with
SS0/SS1. Yet, while this is a noticeable difference, the relationship between the illness
condition and all four stable states determines its overall placement in the landscape and
the resulting topology.
Blood profiles for the model and illness conditions under challenge were separately
added to the healthy blood profile topological networks (Figure 7). Unlike the at-rest
condition, the non-trauma GWIL and trauma GWIH under challenge conditions (Figure 7A
and Figure 7B, respectively) present with very similar topologies (RMSD = 0.02), as do
the non-CORT- and CORT-treated DFP LPS mouse models, although to a lesser degree
(RMSD = 0.05). Comparison of GWI illness conditions to the mouse conditions under
challenge shows that the GWIL condition is still most closely matched by the non-CORT
treated mouse model (RMSD = 0.02) (Figure 7C) rather than the CORT-treated model
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(RMSD = 0.03) (Figure 7D). However, the degree of difference is much less. Again, the
GWIH condition showed a better match with the CORT-treated model (RMSD = 0.02),
being a better match over the non-CORT-treated model (RMSD = 0.04), again with smaller
differences. Unlike the at-rest conditions, the agreements between the trauma/stressed
states share the same ordering of differences between the stable state positions with only
minor differences to account for the small non-zero RMSDs. In all cases, the conditions
show the closest alignment with stable state SS4/SS5, followed by SS2, SS3, and finally
SS0/SS1.
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exercise. (B) Topology of the distance between the simulated stable states for GWIH at peak exercise.
(C) Topology of the distance between the simulated stable states of mice receiving a course of pure
drinking water, an injection of DFP, and a follow-up injection of LPS. (D) Topology of the distance
between the simulated stable states of mice receiving a course of drinking water with CORT, an
injection of DFP, and a follow-up injection of LPS.
As it is not possible to assess brain measures in the human cohort directly, adding
brain measures from the mouse models to their blood profiles allows for the discrimination
between SS4 and SS5 while retaining the overall structure observed in the reference brain
and blood profiles (Figure 8A), and therefore infer the probable brain states for the human
cohort groups. Topologically, the non-challenged mouse model, stressed and unstressed,
resembles the blood-only profiles, as do the challenged stressed and unstressed conditions.
For the non-challenged conditions (Figure 8B,C), the Water DFP SL mouse model retains
its closest proximity to SS0/SS1, while the CORT DFP SL mouse model retains closest prox-
imity to SS3. For the challenged conditions (Figure 8D,E), the Water DFP LPS mouse model
is most comparable to the SS5 state, while the CORT DFP LPS mouse model is equidistant
from both SS4 and SS5, with only a slightly longer distance to SS2. The remainder of the
edge orders for all models is also retained from the blood-only comparisons (Figures 6C,D
and 7C,D), save for SS5.
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2.5. Simulated Treatment Cour es
As determined abo e, t GWI blood profiles both align more closely with the SS4/SS5
attractor; however, th blood profiles alone cannot discriminate between these two a tractor
states. The alignment of the mouse profile , GWIL, and GWIH are best pr ented by
th Water-DFP and CORT-DFP models, respectively, bo h at rest (saline) and u der LPS
challenge. The brain profiles of thes mous model suggest that GWIL orbits SS5, while
GWIH orbits equidistant from states SS4 nd 5 closely followed by SS2, all of which are
taken as starting points for the simulation of the treatments. Treatments were simulat d,
allowing for increases in cortisol, ACTH, and testosterone, inhibition of gluc corticoid
receptors, and bidirectional modulation of all peripheral cytokines.
For the SS5 start state, a minimum of three treat ent targets ere needed to obtain at
least a 1 return to health (Table 2). The treatment course consisted of an initial phase of
increasing testosterone, followed by an inhibition of CK1 cytokines, including IL-2, IFNγ,
TNFα, and TNFβ, followed by inhibiting the glucocorticoid receptor with some overlap
between these phases. This minimum intervention resulted in a 37% return to health.
Table 2. The three intervention treatments course starting from SS5 results in a 37% return to health.
Treatment tstart tstop
Increase Testosterone 1 43
Inhibit CK1 21 83
Inhibit GRD 75 99
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For the SS4 start state, again, a minimum of three treatment targets were needed to
obtain at least 1% return to health (Table 3). The treatment course consisted of a continual
treatment of inhibiting the pro-inflammatory cytokine IL-6, which contained an initial phase
of inhibiting CK1 cytokines including IL-2, IFNγ, TNFα, and TNFβ, followed by a phase of
inhibiting the glucocorticoid receptor with no overlap between these two contained phases.
This minimum intervention resulted in an improved 61% return to health over the SS4
prescribed treatment course.
Table 3. The three intervention treatments course starting from SS4 results in a 61% return to health.
Treatment tstart tstop
Inhibit MK6 1 100
Inhibit CK1 8 40
Inhibit GRD 77 99
Finally, for the SS2 start state, only two interventions were needed to obtain at least
a 1% return to health (Table 4). This two-intervention treatment course consisted of a
near overlapping continual treatment of inhibiting pro-inflammatory cytokine IL-6 with
inhibition of the glucocorticoid receptor. This dual combination strategy resulted in a
31% return to health, less than both the SS4 and SS5 three-target treatments, but with less
intervention overall.
Table 4. The two intervention treatments course starting from SS2 results in a 31% return to health.
Treatment tstart tstop
Inhibit MK6 1 96
Inhibit GRD 7 93
3. Discussion
The wide range of symptoms observed in GWI is consistent with underlying neuroin-
flammatory processes. Ultimately, these processes have effects beyond the CNS, affecting
immune and endocrine function in the periphery and ultimately giving rise to the symptom
presentations in the illness. As the presence of PTSD symptoms exacerbates the overall
clinical symptoms of GWI [19], and PTSD shows its immunological dysfunction [21–24],
it is reasonable to assume that past trauma may be used to delineate two biological GWI
subgroups. In the context of the neuroimmune model presented here, the high and low
trauma GWI group blood profiles at rest share the closest proximity with the same altered
regulatory state marked by elevated HPA axis activity, depressed HPG activity, depressed
NK activity, and increased MK2, CK1, CK17, MK1, MK2, MK6, MK15, CTL, Th17B, and
Th17(23) activity, albeit not with complete agreement. Under exercise challenge, these two
groups converge to this common point and are nearly identical.
These results alone suggest that the absence and presence of PTSD do not delineate
specific biological subtypes of GWI. However, when projected into the neuroimmune model
state space, these two subtypes present as topologically distinct at rest, suggesting that the
underlying biological regulation between these two groups are unique. These modeling
results are consistent with past research into the biomarkers/biosignatures of GWI. The
difference in biological profiles between GWI and the controls has been shown to be more
distinct and consistent under an exercise challenge [6]. At rest, GWI profiles are variable
and sometimes present with inconsistent results [63,64]. Past biomarker/biosignature
studies have not grouped GWI in terms of prior trauma; as such, the distinct GWIL and
GWIH subgroups intermixed at rest would be expected to yield mixed and inconsistent
results compared to controls as the proportion of each group varies. However, under
exercise challenge, as the profiles of GWIL and GWIH converge, the typical neuro-endocrine
immune signature emerges as different from the control.
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The difference between the profiles of GWIL and GWIH at rest is due to their relation
to the remaining stable regulatory patterns that define their difference in blood alone. As
neither of the subgroups aligns completely with any of the defined stable states, there are
factors not accounted for in the model to hold the subgroups at their baseline positions.
This may be in both the periphery or in the brain portions of the network model. Further
refinement of the granularity of the peripheral endocrine and immune system elements is
thus hypothesized to further define these two subgroups in human subjects.
The topological alignment between the GWI subtypes and the animal models suggests
that the use of corticosterone priming of the neuroinflammatory response seems to best
represent GWI with past traumatic events (i.e., GWI with probable PTSD; GWIH), while
the animal model without corticosterone priming best represents GWI alone (i.e., GWI
without probable PTSD; GWIL). However, while the animal models at rest topologically
resemble the GWIH and GWIL states, the challenged condition in human and nonhuman
animals is more closely aligned and represents the best scenario for assessing treatments.
By applying our genetic algorithm methodology to these starting conditions, we
identify three possible candidate treatment courses for GWI. The first, involving increasing
testosterone, followed by inhibiting IL-2, IFNγ, TNFα, or TNFβ, followed by inhibiting
the glucocorticoid receptor, applies to both the GWIL and GWIH subgroups and is the
only predicted treatment course for GWIL based on this model. This treatment course is
consistent with past findings regarding Th1 immunity and glucocorticoids in GWI and
our previously predicted treatment course for GWI involving modulating Th1 immunity
via inhibiting TNFα and TNFβ via etanercept, followed by blocking the glucocorticoid
receptor with mifepristone [65,66], except for the addition of the testosterone pre-treatment.
There are many anecdotal reports that male veterans with GWI suffer from low levels
of testosterone; however, there is a lack of formal studies investigating this claim. Studies
of self-reported sexual dysfunction have included reports of decreased libido, erectile
dysfunction, discomfort or pain during intercourse, and a burning sensation after sex. A
primary study on sexual dysfunction in a Danish cohort of Gulf War veterans found that
these sexual problems were associated with traumatic events and not related to differences
in major reproductive hormone parameters [67,68]. However, these studies concern Gulf
War veterans, which who do not necessarily meet the criteria for Gulf War Illness. Fur-
thermore, Danish troops were in the Persian Gulf region after the war as peacekeepers
and were not exposed to sarin [69]. Other studies investigating the testosterone levels
in Gulf War veterans compare groups with high or low exposure to depleted uranium.
These studies have similarly found no statistically significant differences between these
groups in endocrine function (i.e., including serum follicle-stimulating hormone, luteiniz-
ing hormone, prolactin, and total testosterone) [70–76]. This, however, does not rule out
the possibility of low testosterone in veterans with Gulf War Illness compared to sedentary
Gulf War-era veteran controls. Several studies in rats have identified anti-androgenic effects
(i.e., reduced levels of testosterone, follicle-stimulating hormone, and luteinizing hormone,
as well as testicular shrinkage) of the GW-relevant organophosphate acetylcholinesterase
inhibitor and pesticide, chlorpyrifos [77–81]. Studies investigating the diffuse chronic pain
of fibromyalgia, which has commonalities with other chronic pain conditions such as PTSD
and Gulf War Illness, have suggested low or deficient testosterone serum levels that likely
cause an inflamed nociceptive nervous system [82]. This hypothesis is supported by the
relief of chronic pain symptoms following the application of testosterone gel [83]. Therefore,
while our modeling efforts indicate the potential for low testosterone in GWI [38,39,66,84],
which is supported by trends in our data, there is a lack of conclusive findings in this area;
thus, a more formal analysis of endocrine dysfunction in GWI accounting for confounding
factors, such as age and BMI, is needed.
Beyond the first three-intervention treatment course predicted for GWI in total, our
modeling efforts also identified two additional treatment courses for GWIH, each with its
separate advantages and disadvantages. The second course is another three-intervention
treatment strategy that involves a continuous inhibition of IL-6, which contains an inhibi-
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tion of IL-2, IFNγ, TNFα, or TNFβ, followed by inhibition of the glucocorticoid receptor
with no overlap. Like the addition of testosterone suggested for the first treatment course,
this treatment course is consistent with the previously reported treatment course of mod-
ulation of Th1 immunity followed by blocking the glucocorticoid receptor, except here it
involves the addition of a continual inhibition of IL-6 during the treatment course. Here, the
potential drawback is both the continual administration of a potent IL-6 immune inhibitor
over the treatment course in addition to another interspersed IL-2, IFNγ, TNFα, or TNFβ
immune inhibitor. The advantage of this three-intervention treatment is the suggested
doubling of the overall return to health rate compared to the first.
Finally, the third treatment course is a two-intervention strategy involving simulta-
neous inhibition of IL-6 and the glucocorticoid receptor. This is a novel treatment course
for GWIH of minimal intervention with a comparable return to the health rate of the first
treatment course. It does involve the continual administration of a potent IL-6 immune
inhibitor over the treatment course in conjunction with glucocorticoid inhibition but does
not have the same drawback as the second treatment course involving simultaneous dual
immune inhibition.
The inhibition of IL-6 for the treatment of GWI with probable PTSD makes sense
in the light of the increased levels of IL-6 found in PTSD. For example, elevated serum
IL-6 and IL-6 receptor concentrations have been found in PTSD following accidental man-
made traumatic events [85], and enhanced IL-6 response to the mental stress following
myocardial infarction [86]. A meta-analysis and meta-regression of 8057 studies comparing
inflammatory markers between patients with PTSD and healthy controls found increased
levels of IL-6 that are more pronounced in PTSD without major depressive disorder and
for those not taking medication, with the severity of PTSD being positively associated
with IL-6 levels [87]. Many animal models have also been used to understand how the
brain responds to trauma and investigate treatments that can reduce symptoms of PTSD.
Despite the varied methodologies used to model PTSD, rodent models have consistently
shown elevated inflammatory markers, including IL-6, both in the central nervous system
and peripherally after exposure to inescapable shock [88], chronic variable stress [89,90],
and social defeat [91]. This indicates that IL-6 is a feature of PTSD-related pathology both
in human patients and in rodent models. Interestingly, treatments that alleviate PTSD-
related symptoms also reduce IL-6. This finding is corroborated with anti-inflammatory
drugs such as minocycline, which reduces IL-6 and anxiety-related behaviors in rodent
models of PTSD [92,93]. Not only do these anti-inflammatory drugs have anxiolytic effects,
indicating that reducing pro-inflammatory cytokines could ameliorate PTSD, but also the
frontline drugs used to treat PTSD, serotonin selective reuptake inhibitors (SSRIs), reduce
inflammatory markers such as IL-6 [92,94]. Taken together, trauma that induces PTSD-
like features in nonhuman animals increase IL-6 and treatments that reduce anxiety after
trauma also reduce IL-6, so it follows that IL-6 may play a role in the mechanism of PTSD,
but most data supporting this role of IL-6 are indirect. More recently, inhibiting IL-6 using
antibodies or transgenic silencing showed that IL-6 plays a causal role in the enhanced
fear memory commonly seen in PTSD [95]. Thus, animal models of PTSD indicate that
inflammatory markers, including IL-6, are both a feature and a mechanism underlying
PTSD.
4. Materials and Methods
4.1. Discrete Ternary Logical Analysis
The discrete ternary logical network analysis used in the present work is an extension
of a methodology proposed by Mendoza and Xenarios [40] and Thomas [43], and has
been reported previously by our group [38,39,53,66]. We encode documented feedback
mechanisms within the endocrine-immune system using only the direction (source and
target) and type (activator or inhibitor) of interaction. As data describing the magnitude of
changes remains limited, we consider all cell types to be equally responsive to the actions
of the cytokines for which they express receptors. Accordingly, we also consider cytokine
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synthesis to be equivalent regardless of cell type. Using this formalism, we determine the
number and type of stable resting states supported by the regulatory circuitry as well as
the specific qualitative endocrine-immune signatures at each of these stable points without
requiring detailed kinetic information; that is, we determine where the system would
eventually come to rest even though we may not know how quickly this equilibrium will
be reached.
In this model, signaling molecules and cell types are represented as individual vari-
ables, each capable of adopting three discrete states: −1 (downregulated), 0 (nominal),
and 1 (upregulated). At any point in time t, the state of a system with n variables can be
represented by the vector
→
x (t), such that
→
x (t) = (x1(t), x2(t), · · · , xN(t)), (1)
where xi(t) is the state of the ith variable of the n variable system at time t. The image
vector
→
x (t + 1) describes the preferred state towards which the system evolves in the next
time increment. The state value of the image vector for the ith variable is determined from
its current state and a set of balanced ternary logic statements based on the current value of
variable and the mode of action (i.e., activate or inhibit) of the neighboring input variables.
These logic statements are expressed as follows (Equation (2)):
xi(t + 1) =

(




xIi1(t) ∨ xIi2(t) ∨ · · · ∨ xIiY(t)
)(




xIi1(t) ∨ xIi2(t) ∨ · · · ∨ xIiY(t)
) , (2)
where the ∇, ∨, and ¬ symbols are ternary HIGH/LOW PASS, OR and NOT operators,
xAij is the state of the i
th variable’s jth activator, and xIij is the state of the i
th variable’s
kth inhibitor. The ternary operators given in Equation (2) are described in further detail
in [38]. The first entry in Equation (2) is used when the variable possesses X activators
and Y inhibitors, the middle when the variable has only X activators, and last when the
activator has only Y inhibitors. While the number of X activators and/or Y inhibitors for a
given variable may remain static, they may also be allowed to change based on predefined
conditions, such as the state of one or more variables. In the case where the number of X
activators and/or Y inhibitors are conditionally dependent, Equation (2) is modified to
reflect the number of activators or inhibitors allowed by the predefined conditions and the
current state of the network system. In this case of this model conditional edges are only
allowed if the EndothelialCells node is −1.
4.2. Monte Carlo Simulation of State Evolution
Following [38], the evolution of state transitions supported by the model was ana-
lyzed by developing a Monte Carlo simulation algorithm. From any initial starting state,
allowable state transitions are determined based on Equation (2). Applying Equation (2)
to each variable in the model for the state of the system at time t,
→
x (t) defines the image
vector
→
x (t + 1) for the next timepoint. With
→
x (t + 1) defined, the system is updated asyn-
chronously allowing only one variable to change at each timestep following the generalized
logical analysis of Thomas [43]. According to this method, one variable slated to change
by the image vector is chosen at random using a uniform equal distribution and used
to generate the next allowable state; that is, if the ith variable of the state vector, xi(t), is
chosen at random to evolve it is moved one step towards its preferred image xi(t + 1)
(e.g., if xi(t) = −1 and xi(t + 1) = 1, then xi(t + 1) is set to 0). Thus, for each current
state of the system there are potentially several subsequent states towards which it may
asynchronously evolve. States for which the image vector is the same as the current state
vector are considered stable (steady states, attractors, basins, etc.), and do not evolve further
in time. The Monte Carlo procedure is performed until such a stable state is reached. Exe-
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cuting the simulation multiple times gives a distribution of paths that is used to determine
the behavior of the system from any given start state.
4.3. Participants/Procedure
All participants signed an informed consent approved by the Institutional Review
Board of the Miami Veterans Affairs Medical Center. Ethics review and approval for data
analysis was also obtained by the IRB of Nova Southeastern University.
Participants were recruited via the Miami Veterans Affairs (VA) Medical Health Center
in two cohorts funded under a Veterans Affairs Merit award (GWI: n = 27, healthy controls
(HC): n = 19) and a Department of Defense Gulf War Illness Research Program award
(W81XWH-09-2-0071) (GWI: n = 24, HC: n = 19), both of which compared male veterans
with GWI to HC. Therefore, the full sample for the multivariate and univariate analyses
included n = 51 male veterans with GWI in addition to n = 38 healthy controls.
Inclusion criteria for GWI participants was derived from Fukuda et al. [96] and
consisted in identifying veterans deployed to the theater of operations between 8 August
1990, and 31 July 1991, with one or more symptoms present for 6 months from at least
2 of the following: fatigue, mood, and cognitive complaints, as well as musculoskeletal
complaints. Participants were in good health prior to 1990 and had no current exclusionary
diagnoses defined by Reeves et al. [97]. This includes exclusion of major dementias
of any type and alcoholism or drug abuse, medical conditions including organ failure,
rheumatologic disorders, and use of medications that impact immune function, such
as steroids or immunosuppressants. Collins et al. [98] supports the use of the Fukuda
definition in GWI. Control participants consisted of Gulf War era veterans self-defined
as healthy with no exclusionary diagnoses, and sedentary (no regular exercise program,
sedentary employment).
All participants were subjected to a standard maximal graded exercise test to stimulate
their immune response and blood samples were collected at rest (T0) and peak effort (T1)
as previously described [6].
4.4. Human Blood Analysis
Plasma was collected immediately upon receiving. EDTA Plasma was collected
by centrifugation, 2000× g for 15 min, and frozen immediately. Cytokine analysis was
performed using Quansys chemiluminescent assays (Quansys Biosciences, Logan, Utah).
The Quansys Imager, driven by an 8.4-megapixel Canon 20D digital SLR camera, supports
96-well plate-based chemiluminescent imaging. The Q-Plex™ Human Cytokine Screen is
a quantitative ELISA-based test where distinct capture antibodies have been absorbed to
each well of a 96-well plate in a defined array. Custom 16- and 18-multiplex assays were
used in the Veterans Affairs Merit award and a Department of Defense Gulf War Illness
Research Program award (W81XWH-09-2-0071) studies, respectively.
The 16-multiplex panel includes TNFα, TNFβ, IL-1α, IL-1β, IL-6, IFN-γ, IL-12, IL-2,
IL-15, IL-8, IL-5, IL-17, IL-23, IL-10, and IL-13 (Fletcher et al. (2009)). For the standard
curves, we used the second order (k = 2) polynomial regression model (parabolic curve),
Y = b0 + b1X + b2 × 2.... + bkXk, where Y caret is the predicted outcome value for the
polynomial model with regression coefficients b1 to k for each degree and y intercept b0.
Quadruplicate determinations were made, i.e., each sample was run in duplicate in two
separate assays.
The 18-multiplex panel includes TNFα, TNFβ, IL-1α, IL-1β, IL-6, TNF-RI, TNF-RII,
IFN-γ, IL-12, IL-2, IL-15, IL-8, IL-5, IL-17, IL-23, IL-10, and IL-13. Briefly, plasma samples
are thawed at 4 ◦C overnight. Samples are plated in duplicate following the manufacturer’s
protocol. The plates were read at 270 s using the Q-view Imager LS (Quansys). Individual
cytokine concentrations were obtained using image analysis software (Q-view, Quansys
Biosciences). Sample concentrations were calculated from standard curves created by a
five-parameter logistic regression (5PL) with
√
y weighting. The average value from each
duplicate was then used for subsequent analyses.
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To account for 16-plex and 18-plex differences, data were separated and standardized
by z-scoring. The two data sets were then combined and reverse z-scored using the mean
and standard deviation of the 18-plex dataset to scale the 16-plex data to the 18-plex set.
Following this, the dataset was normalized using min–max normalization so the final data
values ranged between 0 and 1. Normalized cytokine values are given in Table S1.
4.5. Animals and Dosing
All animal experiments were performed using protocols approved by the Centers
for Disease Control—National Institute for Occupational Safety and Health Institutional
Animal Care and Use Committee (CDC-Morgantown IACUC) and the United States Army
Medical Research and Development Command Animal Care and Use Review Office (US-
AMRDC ACURO). Adult male C57BL/6J mice (8–12 weeks of age; weighing approximately
22 g) were purchased from Jackson Labs (Bar Harbor, ME, USA). Mice were single housed
in a temperature- (21 ± 1 ◦C) and humidity-controlled (50 ± 10%) room under filtered
positive-pressure filtration and a 12 h light/dark cycle (lights on at 0600 EDT); mice were
given ad libitum access to food (Harlan 7913 irradiated NIH-31 modified 6% rodent chow)
and water.
For dosing, mice were randomly placed into groups (n = 5/group) and either remained
on regular drinking water or pretreated with CORT (Steraloids Inc., Newport, RI, USA) in
the drinking water (200 mg/L in 0.6% Ethanol (EtOH; Sigma-Aldrich, Inc., St. Louis, MO,
USA)) ad libitum for 4 days followed by exposure to DFP (4 mg/kg, i.p.; Sigma-Aldrich, Inc.,
St. Louis, MO, USA) or saline(0.9%) on the 5th day. Following this exposure combination,
modeling the initiating factors for GWI [50,51,54,61], mice were repeatedly exposed to
4-day bouts of CORT every other week (4 days on/10 days off) for a total of 11 weeks.
Following the final 4-day CORT exposure, mice were challenged with the inflammatory
bacterial endotoxin lipopolysaccharide (LPS; 0.5 mg/kg, s.c.; Sigma-Aldrich, Inc., St. Louis,
MO, USA) or saline and sacrificed by decapitation at 6 h following this exposure. Frontal
cortex and blood serum samples were collected as previously described [50,51,54,61]. Due
to mortality associated with DFP exposure, the DFP and DFP LPS groups comprised an n
of 2 and 3, respectively. A schematic of the dosing paradigm is shown in Figure 2A.
4.6. Mouse Serum Cytokine Analysis
Cytokine levels were measured in mouse serum (n = 2–5/group) as previously de-
scribed [61]. Briefly, serum samples were analyzed using Q-Plex™ Mouse Cytokine Screen
(16-plex), Quansys Imager, and Quansys reagents (Quansys Biosciences, Logan, Utah). Cy-
tokine levels are expressed as pg/mL and presented as the mean ± SEM in Supplementary
Table S2.
4.7. qRT-PCR Analysis of Mouse Brain Cytokines
mRNA was isolated and cytokine expression measured by qRT-PCR analysis as pre-
viously described [50,99]. Briefly, total RNA was isolated from the frontal cortex using
Trizol Reagent (Thermo Fisher Scientific, Waltham, MA, USA), Phase-lock heavy gel (Ep-
pendorf AG, Hamburg, Germany), and RNeasy mini spin columns (Qiagen, Valencia, CA,
USA) following the manufacturer’s instructions. PCR analysis of the housekeeping gene,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and of the proinflammatory medi-
ators, TNFα, IL-6, CCL2, IL-1β, leukemia inhibitor factor (LIF), and oncostatin M (OSM)
was performed in an ABI7500 Real-Time PCR System (Thermo Fisher Scientific) in combi-
nation with TaqMan® chemistry. Relative quantification of gene expression was performed
using the comparative threshold (∆∆CT) method to normalize expression changes against
the GAPDH control, as well as normalize the expression changes to the corresponding
saline-treated controls (Figure 2C, and Table S3). Statistical significance (p ≤ 0.05) was
determined by two-way ANOVA followed by multiple comparisons using Fisher’s Least
Significant Difference in SigmaPlot (v. 14, Systat Software, Inc., San Jose, CA, USA).
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4.8. Comparison of the Gene Expression Data to the Model-Predicted States
Following [38], to check the validity of our model, we compared stable states predicted
by the latter to gene expression profiles measured experimentally in the mouse model of
Gulf War Illness [51] in both brain and blood, and to blood measures using the cohort of
male veterans. Brown’s theoretical approximation [100] of Fisher’s statistics was used as a
measure of similarity between a given model-predicted state and the expression profile
measured in a subset of genes corresponding to the cellular and molecular entities used
in our model, as done in our previous work [38,39,66,84]. Fisher’s statistics provide a
meta-analysis technique to combine probabilities and obtain the overall significance of a set







where n is the number of measurable variables and pi are the corresponding p-values
under the null hypothesis, has a χ2 distribution with 2N degrees of freedom assuming the
hypothesis tests are independent. As evidenced by the connectivity of the system studied
here, these model entities do not express independently. As a result, direct application
of this test statistic is not valid since the assumption of independence is violated. To
accommodate this, Brown [100] suggested a method for combining non-independent tests.
If the tests are not independent, then the statistic T0 has mean m = 2N and variance (σ2),
given as




























, −0.5 ≤ ρij < 0
(5)
with ρij being the unadulterated correlation between variable i and variable j. Finally, the
overall significance p of a set of non-independent tests is calculated using the statistic T
which under the null hypothesis follows the central χ2 distribution, where T = T0/c with
2N/c degrees of freedom and c = σ2/4N.
Here, we test if the expression levels of the subset of genes corresponding to the
cellular and molecular entities used in our model align with a given model-predicted
discrete state profile. Our null hypothesis is that the experimental measures do not align
with model predictions of greater than control (normal), lower than the control or in
alignment with the control levels. First, the p-values for individual variables, pi, were
calculated using two-sample t-tests comparing the expression levels in ill subjects with
those measured in healthy controls. Where the model predicts marker expression to be high
(+1), a ‘right-handed’ one-tailed test was used to confirm that the measured expression
levels are significantly greater than the reference control (0). Conversely, a ‘left-handed’ test
was used when the model predicted a low (−1), to confirm that the measured expression
levels are on average significantly lower than the reference control (0). For the case where
the model predicted normal expression levels for a variable (0), a two-tailed t-test was
used. However, the p-value from the two-tailed test, ptwo-tail, gives the probability that
there is an observable difference between illness and control, which is the null hypothesis.
To rectify this, when comparing to a model-predicted variable of 0 we took the p-value
to be pi = 1 − ptwo-tail, giving the probability of obtaining the predicted value when the
null hypothesis is true. The unadulterated correlation values ρij between two variables
i and j were calculated in the control groups as the pairwise Pearson’s linear correlation
coefficient between variables. Aggregate p-values between the predicted model states
were determined via Brown’s method above, where values between the predicted states
that were found to disagree with the p-values for individual variables, pi, were taken as
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1. Conversely, when the values between the predicted states were found to agree, pi was
assigned a standard minimum value for significance of 0.05 to avoid numerical instability
in the calculation of the combined χ2 statistic T0. Hold-out cross validation was performed
by randomly splitting the healthy control dataset evenly in two and performing the above
method 100 times. This resulted in a maximum of 94% of the runs, finding that the test
group aligned with the healthy SS0 stable state with an even distribution of the remaining
cases being assigned to the other alternate stable states (see Figure S1).
A comparison of the measured states with the model-predicted stable states is best vi-
sualized by projecting the multi-dimensional co-expression profiles into a two-dimensional
space using multidimensional scaling. Here, the dissimilarity matrix defined by the p-
value is scaled such that the 2D Euclidean distances between points approximate of the
corresponding dissimilarities. This is performed using the function mdscale in MATLAB
to minimize Kruskal’s stress criterion normalized by the sum of squares of the dissimi-
larities. To maintain the relative structure of the healthy control baseline-defined stable
state positions between the conditions, the weight of the added illness condition distances
was set at ten percent of the distances defining the stable state positions. This value was
chosen to keep the RMSD of the stable states between conditions equivalent to two decimal
places. The resulting 2D plot illustrates the statistical significance of separation between
the measured and predicted co-expression patterns. To compare the plots between the
conditions, all the resulting 2D plots were aligned with the human baseline condition via
an affine geometric transformation based on the model-predicted stable state positions via
the MATLAB function fitgeotrans.
To provide a measure of agreement between conditions, the root mean square devia-














where xji and y
j
i are the horizontal and vertical positions of the i
th point of n total points in
plot j.
4.9. Simulating Intervention Courses
To identify a robust sequence of interventions capable of moving the system from a
pathological mode of regulation to that of normal health, we evolved solutions combining
a specific choice of treatment targets as well as the sequence, spacing, and type of external
perturbation. For each of these candidate treatment courses, simulations were conducted
to evaluate the occurrence of normal homeostasis. Specifically, each clinical intervention
was represented as a treatment vector with n variables. Interventions applied to the system




T(t) = (T1(t), T2(t), · · · , TN(t)) (7)
where Ti is a ternary value describing the effect of the clinical treatment on the ith element
of the system: −1 (inhibiting), 0 (untreated), and 1 (supplementing). At those times where
an intervention is being applied, the image vector
→
x (t + 1) describing the preferred state
towards which the system should evolve is now defined as
→





as opposed to the unperturbed logic described in Equation (2). Due to the ternary nature
of this system no value can extend beyond the range of −1 to 1; hence, values beyond this
range were rounded accordingly (i.e., if xi(t) = 1 and Ti(t) = 1, then xi(t + 1) = xi(t) +
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T(t) = 2 is rounded to 1). At times t when there is no treatment applied (i.e., all T(t) = 0),
the state transition continues according the logic in Equation (2).
4.10. Genetic Algorithm for Optimizing Treatment Course
A first mapping of the illness basin of attraction consisted of a series of simulations
where we first allowed for a one-time simultaneous perturbation of two or more variables at
the outset only without subsequent intervention. We then expanded on this by performing
a global search to find an optimal series of single target interventions separated in time,
which reliably led to health. A Genetic Algorithm (GA)-based search [66] was used to
optimize this treatment course, as its form naturally accommodates the discrete definition of
each system state. A treatment course vector
→



























is the jth intervention treatment vector starting at time point tjstart
and ending at tjstop. Due to the asynchronous nature of the model each treatment vector
→
T only contains a single target intervention Ti that affects the ith element variable in the
system at any given time step.
The GA starts by generating a population of 1000 candidate treatment courses each
composed of a specific number of randomly selected interventions applied at random time
points. The response of the system to each treatment course in this initial generation of
candidates is then simulated for 1000 timesteps. Over the course of these time steps the state
of the system evolves according to Equation (2), except at those times when interventions
are applied. At these intervention events the state transition follows Equation (5). These
1000 iterations provide a distribution of paths that are then ranked according to a fitness
function based on the number of times a treatment successfully reaches the healthy stable
state (% HHM). After all treatments in the generation have been ranked, the top 10% are
retained without change for the next generation. Thus, treatments generated by the GA
that have a higher probability of leading to the HHM are re-executed and re-evaluated
over many generations. The remainder of the next generation of candidate solutions is
created by choosing random pairs from the total set of treatment courses (including the top










1 for the next generation, such that all treatments in
→
C1 preceeding
s, and all treatments in
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The response to the new treatment courses, including members of the previous top
10th percentile, are then simulated once again and ranked as a new generation. This process
is continued iteratively for 1000 generations. The final treatment course with the highest %
HHM was taken as the best treatment solution for a given run. The overall best treatment
course was chosen from the 100 repeated GA runs.
5. Conclusions
Our simulations predict treatment avenues for GWI in totality, as well as specific
treatments for GWI with probable PTSD. However, it must be noted that the predictions
presented here are based on an idealized model of immune interactions across the BBB. The
alignment of experimental data with model predictions does suggest that GWI aligns with
a state characterized by BBB dysfunction as predicted by the model; however, additional
molecular and biochemical evidence (e.g., small molecule leakage, albumin leakage, MMP
activation, and monocyte adhesion to the microvascular endothelium) are needed to make
a definitive claim concerning BBB function in GWI and GWI mouse models. As such, future
research in this area is warranted. Overall, the advantage of this modeling methodology is
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also one of its limitations in that it does not account for detailed kinetics. The magnitude
and transition time of the interactions between elements of the extended neuroendocrine-
immune system are not predicted, rather only the logical feasibility of these interventions
is assessed. While refinement of the simulation parameters based on detailed measurement
of the model elements can serve to improve the accuracy of the simulation timing and
magnitude, the underlying logic is not affected. Regardless, even with these refinements,
the safety and efficacy of any predicted treatment strategy must be determined clinically.
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